Advancing human health through evolutionary insights

Fauna Bio is an AI-driven drug discovery company pioneering the use of cross-species comparative genomics to uncover therapeutic targets inspired by nature’s most resilient and disease resistant mammals. Through its proprietary FaunaBrainTM AI platform, the company integrates multi-omic data sets from over 292 species, 24 tissues, and 21 timepoints to drive target discovery across neurologic, cardiologic, metabolic and retinal diseases. In 2023, Fauna announced a $494M multi-year partnership with Eli Lily to apply its platform to drug discovery in obesity, further validating the company’s translational and commercial potential.